Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer

[1]  Yang Xu,et al.  The gain of function of p53 cancer mutant in promoting mammary tumorigenesis , 2013, Oncogene.

[2]  D. Walerych,et al.  The rebel angel: mutant p53 as the driving oncogene in breast cancer , 2012, Carcinogenesis.

[3]  L. Gu,et al.  MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia , 2011, Molecular and Cellular Biology.

[4]  Eugene S. Kim,et al.  Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma , 2011, Angiogenesis.

[5]  F. Westermann,et al.  Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.

[6]  M. Saha,et al.  MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity , 2010, Cancer biology & therapy.

[7]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[8]  L. Huang,et al.  Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. , 2009, Carcinogenesis.

[9]  D. Durden,et al.  Regulation of XIAP translation and induction by MDM2 following irradiation. , 2009, Cancer cell.

[10]  M. Raffeld,et al.  MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma , 2009, Clinical Cancer Research.

[11]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[12]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[14]  B. K. Park,et al.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination. , 2008, Cancer research.

[15]  Jing Wang,et al.  Evaluation of biological pathways involved in chemotherapy response in breast cancer , 2008, Breast Cancer Research.

[16]  H. Findley,et al.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.

[17]  M. Ashcroft,et al.  Regulation of angiogenic factors by HDM2 in renal cell carcinoma. , 2008, Cancer research.

[18]  K. Phoenix,et al.  Double-Stranded RNA-Binding Protein Regulates Vascular Endothelial Growth Factor mRNA Stability, Translation, and Breast Cancer Angiogenesis , 2007, Molecular and Cellular Biology.

[19]  L. Mayo,et al.  Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.

[20]  F. Agani,et al.  Mdm2 and HIF‐1α interaction in tumor cells during hypoxia , 2005 .

[21]  Hui Wang,et al.  Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. , 2005, Current cancer drug targets.

[22]  Ruiwen Zhang,et al.  p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.

[23]  G. Tortora,et al.  Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer , 2004, Clinical Cancer Research.

[24]  R. Hill,et al.  Hypoxia Enhances Metastatic Efficiency by Up-Regulating Mdm2 in KHT Cells and Increasing Resistance to Apoptosis , 2004, Cancer Research.

[25]  Hui Wang,et al.  Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models , 2004, Clinical Cancer Research.

[26]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[27]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[28]  A. Levy,et al.  A 40-bp RNA Element That Mediates Stabilization of Vascular Endothelial Growth Factor mRNA by HuR* , 2002, The Journal of Biological Chemistry.

[29]  Moshe Oren,et al.  The p53 and Mdm2 families in cancer. , 2002, Current opinion in genetics & development.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  Hui Wang,et al.  Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  K. Claffey,et al.  Regulation of Human Vascular Endothelial Growth Factor mRNA Stability in Hypoxia by Heterogeneous Nuclear Ribonucleoprotein L* , 1999, The Journal of Biological Chemistry.

[33]  A. Sendelhofert,et al.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. , 1998, The American journal of pathology.

[34]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[36]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[37]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[38]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[39]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[40]  T. Nielsen,et al.  MDM2 protein expression is a negative prognostic marker in breast carcinoma , 2006, Modern Pathology.

[41]  F. Agani,et al.  Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. , 2005, Journal of cellular physiology.

[42]  W. Gu,et al.  Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. , 2003, The Journal of biological chemistry.

[43]  R. Ralhan,et al.  Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. , 2002, European journal of cancer.